Drug · CHEMBL359744
DOXORUBICIN HYDROCHLORIDE
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. DOXORUBICIN HYDROCHLORIDE. Drugs and targets, record CHEMBL359744. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL359744
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Brand names
Adriamycin, Adriamycin pfs, Adriamycin rdf, Caelyx, Caelyx pegylated liposomal, Celdoxome pegylated liposomal, Doxil, Doxil (liposomal), Doxorubicin hydrochloride (liposomal), Doxorubicin hydrochloride component of imx-110, Myocet, Myocet liposomal (previously myocet), Rubex, Zolsketil pegylated liposomal
- ChEMBL
- Other names
Adriablastina cs, Adriamycin, hydrochloride, Doxorubicin citrate, Doxorubicin citric acid salt, Doxorubicin hcl, Doxorubicin liposomal complex of the hydrochloride, Doxorubicini hydrochloridum, Hydroxydaunomycin hydrochloride, Liposomal doxorubicin hydrochloride
- ChEMBL
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| TOP2A | DNA topoisomerase 2-alpha | DNA topoisomerase II alpha inhibitor | INHIBITOR | https://conductscience.org/library/genes/7153 |
Source ChEMBL
Diseases135
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 135Source Open Targets
See all 135 diseasesTrials525
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 36 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 64 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01190930 | Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma | Phase 3 | 9,350 | 2020-06-23 | doxorubicin hydrochloride | Its name | ClinicalTrials.gov |
| NCT02883049 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations | Phase 3 | 5,949 | 2024-03-12 | doxorubicin hydrochloride | Its name | ClinicalTrials.gov |
| NCT00103285 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | Phase 3 | 5,377 | 2018-07-11 | doxorubicin hydrochloride | Its name | ClinicalTrials.gov |
| NCT00433511 | Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer | Phase 3 | 4,994 | 2019-09-04 | doxorubicin hydrochloride | Its name | ClinicalTrials.gov |
| NCT00011986 | Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer | Phase 3 | 4,312 | 2016-04-19 | doxorubicin hydrochloride liposome | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT00041119 | Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer | Phase 3 | 3,871 | 2017-05-18 | doxorubicin hydrochloride | Its name | ClinicalTrials.gov |
| NCT00070564 | S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer | Phase 3 | 3,294 | 2017-04-17 | doxorubicin hydrochloride | Its name | ClinicalTrials.gov |
| NCT01275677 | Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer | Phase 3 | 3,270 | 2020-09-23 | doxorubicin hydrochloride | Its name | ClinicalTrials.gov |
| NCT00075725 | Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia | Phase 3 | 3,154 | 2015-08-06 | doxorubicin hydrochloride | Its name | ClinicalTrials.gov |
| NCT00014222 | Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer | Phase 3 | 2,104 | 2020-03-10 | doxorubicin hydrochloride | Its name | ClinicalTrials.gov |
1 to 10 of 525
See all 525 trialsComparisons in its trials96
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| All Patients for Induction, MRD Negative vs All Patients for Induction, MRD Positive: Early Marrow Status (EMS) by MRD Status End Induction (Day 29) | 4,378 of 4,609 | 258 of 362 | 4,971 | NCT00103285 | Trial comparisons |
| Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): deaths from any cause | 48 of 1,622 | 61 of 1,628 | 3,250 | NCT01275677 | Trial comparisons |
| Arm I (Chemotherapy) vs Arm II (Chemotherapy, Trastuzumab): serious adverse events | 31 of 1,615 | 96 of 1,625 | 3,240 | NCT01275677 | Trial comparisons |
| Arm I (Doxorubicin, Cisplatin, Paclitaxel) vs Arm II (Paclitaxel, Carboplatin): deaths from any cause | 271 of 647 | 280 of 665 | 1,312 | NCT00063999 | Trial comparisons |
| Arm I (Doxorubicin, Cisplatin, Paclitaxel) vs Arm II (Paclitaxel, Carboplatin): serious adverse events | 217 of 647 | 156 of 665 | 1,312 | NCT00063999 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): Overall Survival | 7 of 487 | 14 of 483 | 970 | NCT03907488 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): Event-free Survival (EFS) | 52 of 487 | 91 of 483 | 970 | NCT03907488 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): Progression Free Survival (PFS) | 41 of 487 | 81 of 483 | 970 | NCT03907488 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): deaths from any cause | 7 of 487 | 14 of 483 | 970 | NCT03907488 | Trial comparisons |
| Arm I (Chemotherapy, Nivolumab, Radiation) vs Arm II (Chemotherapy, Brentuximab Vedotin, Radiation): serious adverse events | 140 of 481 | 18 of 476 | 957 | NCT03907488 | Trial comparisons |
1 to 10 of 96
See all 96 comparisons in its trialsPapers from its trials450
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials4
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
| Test | Trials naming it as an outcome | As a primary outcome | Source |
|---|---|---|---|
| Go/No-Go Task | 1 | 1 | ConductCognition |
| Picture Naming Test | 1 | 0 | ConductCognition |
| Stroop Color-Word Test | 1 | 0 | ConductCognition |
| Verbal Fluency | 1 | 0 | ConductCognition |
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL359744
GET https://conductscience.org/api/drugs/v1/CHEMBL359744/diseases?page=2